SCHEMBL2636010

SCHEMBL2636010

O=C(COc1cc(C(=O)O)cc2cc(Cl)cc(Cl)c12)Nc1ccc(OCC(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.49
KMT2A Q03164 8/20 0.49
NPC1 O15118 2/20 0.47
POLB P06746 2/20 0.47
RAB9A P51151 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
MLYCD O95822 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
CETP P11597 1/20 0.41
HPGD P15428 1/20 0.40
S1PR2 O95136 1/20 0.40
S1PR4 O95977 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
XBP1 P17861 1/20 0.40
HTT P42858 1/20 0.40
PAX8 Q06710 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635444 0.90 ALDH1A1 (0.49) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2636145 0.88 MEN1 (0.56) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2635701 0.86 MEN1 (0.60) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2635404 0.85 MEN1 (0.54) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2636136 0.85 POLB (0.48) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2635598 0.84 MEN1 (0.48) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2635689 0.83 KMT2A (0.50) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2635923 0.83 MEN1 (0.52) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2635595 0.83 MEN1 (0.53) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL2635901 0.82 MEN1 (0.51) MEN1KMT2ANPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US claimed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP claimed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO claimed
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 MEN1 932/4885KMT2A 2708/4885NPC1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.